Risk of Weight Gain Associated with Antipsychotic Treatment: Results from the Canadian National Outcomes Measurement Study in Schizophrenia

Canadian Journal of Psychiatry

Volumn 48, Issue 10, 2003, Pages 689-694

  McIntyre, Roger S ^a,b   Trakas, Kostas ^c   Lin, Daryl ^d   Balshaw, Robert ^d   Hwang, Pieway ^c   Robinson, Kimberly ^c   Eggleston, Andrew ^c  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c Janssen Ortho Inc   (Canada)

^d Syreon Corporation   (Canada)

Author keywords

Antipsychotics; Olanzapine; Quetiapine; Risperidone; Schizophrenia; Weight gain

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIPARKINSON AGENT; ANXIOLYTIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; HYPNOTIC SEDATIVE AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADULT; ANTHROPOMETRY; ARTICLE; BODY WEIGHT; CANADA; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; LIPID ANALYSIS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTICENTER STUDY; PROSPECTIVE STUDY; PSYCHOSIS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; SIDE EFFECT; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 0348134925     PISSN: 07067437     EISSN: None     Source Type: Journal    
DOI: 10.1177/070674370304801008     Document Type: Article

References (20)

1. Blin O, Micallef J. Antipsychotic-associated weight gain and clinical outcome parameters. J Clin Psychiatry 2001;62(Suppl 7):11-21.
2. Brown CS, Markowitz JS, Moore TR, Parker NG. Atypical antipsychotics: Part II: adverse effects, drug interactions, and costs. Ann Pharmacother 1999;33:210-7.
3. Buis W. Patients' opinions concerning side effects of depot neuroleptics. Am J Psychiatry 1992;149:844-5.
4. Fleischhacker W, Meise U, Gunther V, Kurz M. Compliance with antipsychotic drug treatment: influence of side effects. Acta Psychiatr Scand Suppl 1994;382:11-5.
5. Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 2001;62(Suppl 7):22-31.
6. Elmslie JL, Mann JI, Silverstone JT, Williams SM, Romans SE. Determinants of overweight and obesity in patients with bipolar disorder. J Clin Psychiatry 2001;62:486-93.
7. Dixon L, Weiden P, Delahanty J, Goldberg R, Postrado L, Lucksted A, and others. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull 2000;26:903-12.
8. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, and others. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156;1686-96.
9. Overall JE, Beller SA. The Brief Psychiatric Rating Scale (BPRS) in geropsychiatric research: I. Factor structure on an inpatient unit. J Gerontol 1984;39:187-93.
10. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83.
11. WHO. Physical Status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. Technical Report Series 854. Geneva: WHO; 1995.
12. Borison RL, Arvanitis LA, Miller BG. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. US SEROQUEL Study Group. J Clin Psychopharmacol 1996;16:158-69.
13. Peuskens J, Link CG. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr Scand 1997;96:265-73.
14. Remington G, Chong SA. Conventional versus novel antipsychotics: changing concepts and clinical implications. J Psychiatry Neurosci 1999;24:431-41.
15. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed. Text revision. Washington (DC): American Psychiatric Association; 1994.
16. Beller SA, Overall JE. The Brief Psychiatric Rating Scale (BPRS) in geropsychiatric research: II. Representative profile patterns. J Gerontol 1984;39:194-200.
17. Gunasekara N, Spencer C. Quetiapine: a review of its use in schizophrenia. CNS Drugs 1998;9:325-40.
18. Brecher M, Rak I, Melvin K, Jones A. The long-term effect of quetiapine (SeroquelTM) monotherapy on weight in patients with schizophrenia. Int J Psychiatry Clin Pract 2000;4:287-91.
19. Wirshing DA, Spellberg BJ, Erhart SM, Marder SR, Wirshing WC. Novel antipsychotics and new onset diabetes. Biol Psychiatry 1998;44:778-83.
20. Pi-Sunyer FX. Comorbidities of overweight and obesity: current evidence and research issues. Med Sci Sports Exerc 1999;31(Suppl 11):S602-S6008.